Montaño-Armendáriz Nathalie, Zamudio-Cuevas Yessica, Fernández-Torres Javier, Martínez-Flores Karina, Luján-Juárez Iván Alejandro
Facultad de Medicina, Universidad Autónoma de Guadalajara, Zapopan, Jalisco, México.
Laboratorio de Líquido Sinovial, Instituto Nacional de Rehabilitación "Luis Guillermo Ibarra Ibarra", Ciudad de México, México.
Rev Alerg Mex. 2023 Jan 4;69(2):78-88. doi: 10.29262/ram.v69i2.1153.
SARS-CoV-2, a virus belonging to the large family of coronavirus, aroused great interest following the outbreak of this new strain reported in 2019, in Wuhan China. Its clinical spectrum is highly variable, ranging from a self-limited disease to an acute respiratory distress syndrome with systemic clinical manifestations (COVID-19), in which the immune system plays a key role in the pathophysiology of this disease and in its severity; several studies show the prevalence of some autoimmune markers suggesting that they may lead to autoimmune states. The most important strategy worldwide to protect the population was the development of vaccines to induce immunity to severe COVID-19; however, vaccines have also been shown to have the ability to produce autoimmune states in a small percentage of the world's population; nevertheless, the best strategy remains vaccination. The aim of this review is to show the current overview of the mechanisms of SARS-CoV-2-induced autoimmunity and post-vaccination for a better understanding and identification of these in the population. Publications from 2019 to 2022 were reviewed in PubMed as the primary search source.
严重急性呼吸综合征冠状病毒2(SARS-CoV-2)是一种属于冠状病毒大家族的病毒,自2019年在中国武汉报告这种新毒株爆发以来,引起了极大关注。其临床谱高度可变,从自限性疾病到伴有全身临床表现的急性呼吸窘迫综合征(新冠肺炎),在这种疾病中,免疫系统在其病理生理学及其严重程度方面起着关键作用;多项研究表明一些自身免疫标志物的普遍性,提示它们可能导致自身免疫状态。全球保护人群的最重要策略是研发疫苗以诱导对严重新冠肺炎的免疫力;然而,疫苗也已被证明有能力在世界一小部分人口中产生自身免疫状态;尽管如此,最佳策略仍是接种疫苗。本综述的目的是展示SARS-CoV-2诱导的自身免疫和疫苗接种后机制的当前概况,以便更好地理解和识别这些情况在人群中的表现。以PubMed作为主要搜索来源,对2019年至2022年的出版物进行了综述。